Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis
(Thomson Reuters ONE) -
Mechelen, Belgium; 27 November 2013 - Galapagos NV (Euronext: GLPG) announced
today that GlaxoSmithKline plan to initiate an exploratory Phase 2 study with
GSK2586184 (formerly GLPG0778) in patients with ulcerative colitis, a third
indication for this investigational molecule, in addition to psoriasis and
lupus.
GSK2586184 is a selective JAK1 inhibitor which was discovered and developed
within Galapagos' inflammation alliance with GSK. GSK in-licensed the molecule
in February 2012, gaining worldwide rights to further development and
commercialization. Galapagos is eligible, without further financial investment
from Galapagos, to receive from GSK ?34M in additional milestones, plus up to
double-digit royalties on global commercial sales of all therapeutic indications
of GSK2586184.
"Inhibition of Janus kinase (JAK) signalling proteins is considered a promising
new therapeutic route to treat inflammatory diseases. Galapagos has discovered
multiple JAK inhibition molecules, three of which have reached the clinic," said
Onno van de Stolpe, CEO of Galapagos.
The Phase 2 studies with GSK2586184 in ulcerative colitis, psoriasis, and lupus
are scheduled to be completed in November 2014, March 2014, and November 2015,
respectively. Further details of all three Phase 2 studies can be found on
www.gsk.com and www.clinicaltrials.gov, under GSK2586184.
About ulcerative colitis
Ulcerative colitis is the most common inflammatory bowel disease worldwide. It
is a disease of the colon (large intestine) characterized by bloody diarrhoea
and there is often a disease pattern of gradual onset, spontaneous remission and
subsequent relapses. Symptoms of frequent urgent diarrhoea, fatigue and
abdominal pain can significantly reduce a patient's quality of life and
productivity.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline comprising six Phase 2 studies (three led by GSK), one
Phase 1 study, five pre-clinical, and 20 discovery small-molecule and antibody
programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and
other indications.
AbbVie and Galapagos signed an agreement in CF where they work collaboratively
to develop and commercialize oral drugs that address two mutations in the CFTR
gene, the G551D and F508del mutation. In the field of inflammation, AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will be
responsible for further development and commercialization of GLPG0634 after
Phase 2B. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment of rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and about to enter Phase 2 studies in
Crohn's disease. Galapagos has another selective JAK1 inhibitor in Phase 2 in
lupus, psoriasis, and ulcerative colitis, GSK2586184 (formerly GLPG0778, in-
licensed by GlaxoSmithKline in 2012). GLPG0974 is the first inhibitor of FFA2
to be evaluated clinically for the treatment of IBD; this program is currently
in a Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and is currently in a First-in-Human Phase 1
study.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
www.glpg.com
Contact
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1745996]
Unternehmensinformation / Kurzprofil:
Datum: 27.11.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 320669
Anzahl Zeichen: 5891
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 212 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
